Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News Archive
News Archive Navigation
News Archive Navigation Language
April 2020
-
Featured News
Novartis Financial Results – Q1 2020
Novartis announced the company’s financial results for the first quarter of 2020.
-
Featured News
World Malaria Day 2020
This year, World Malaria Day is happening as countries around the world are fighting the COVID-19 pandemic.
-
Featured News
Novartis ranks #4 in PatientView’s 2019 corporate reputation survey of patient organizations
The Corporate Reputation of Pharma 2019 global report reflects the findings of a survey conducted by PatientView with patient organizations worldwide.
-
Featured News
World Chagas Disease Day 2020
Novartis is committed to reimagining the fight against Chagas Disease and advocating for an integrated, end-to-end care approach.
-
Featured News
Novartis COVID-19 Response Fund provides support to healthcare workers and communities
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
January 2020
-
Featured News
Novartis 2019 Financial Results
Novartis announces the company’s fourth quarter and 2019 full year financial results.
-
Featured News
Novartis at the World Economic Forum Annual Meeting Davos 2020
From January 21-24 2020, Novartis attended the World Economic Forum Annual Meeting in Davos, Switzerland.
-
Featured News
Novartis at J.P Morgan 2020
From January 13-16 2020, Novartis attended the J.P Morgan Healthcare Conference in San Francisco.
December 2019
-
Featured News
Uncovering profound and under-reported effects on people living with sickle cell disease
Results of the Sickle Cell World Assessment Survey (SWAY) highlight the impact this debilitating disease has on patients and their families.
-
Featured News
Novartis R&D Day
Novartis shares progress in advancing its industry-leading R&D pipeline. We are uniquely positioned to deliver transformational treatments through our scale, focus on innovative medicines, diverse range of therapeutic areas and exposure to cutting-edge platforms.
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 12
- › Next page
Test disclaimer...!!!